0625/26SCR019-18/R12RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
6
Krish Patel, MD
SCRI
Media Outlet Date Article / Coverage
Fierce Pharma 5/30/26 ASCO: With Bispecifics on Its Heels, Incyte Positions
Monjuvi Combo for First-Line DLBCL
Healio 5/30/26 Regimen Confers 'Meaningful' Benefit in Aggressive
Lymphoma, May Become a New Standard
MedPage Today 5/30/26 Frontline Targeted Therapies Plus R-CHOP Boosts PFS in
High-Risk B-Cell Lymphomas
Medscape 5/30/26 Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL
Oncology News
Central
5/30/26 ASCO 2026: First Featured Studies Introduce Potential
New Standards
Rare Disease Advisor 6/1/26 Tafasitamab Combination Regimen Bests R-CHOP Alone in
High-Risk DLBCL
The ASCO Post 6/2/26 Combining Targeted Immunotherapies With Standard
R-CHOP Delays Progression of Aggressive B-Cell
Lymphomas
The ASCO Post 6/10/26 Tafasitamab/Lenalidomide Combination vs R-CHOP in
High-Risk DLBCL: Phase III frontMIND Trial
Debra Patt, MD, PhD, MBA
SCRI a Texas Oncology I The US Oncology Network
Media Outlet Date Article / Coverage
Healio 6/3/26 'This Matters': Hem/onc Fellows Embrace AI but Lack
Formal Training to Guide Its Use
Continued ➔
